Sanofi and Regeneron receive FDA approval for eosinophilic oesophagitis treatment

Sanofi and Regeneron have received approval from the US Food and Drug Administration (FDA) for the use of Dupixent (dupilumab) as a treatment for patients with eosinophilic oesophagitis (EoE).

The drug has been approved for use as a 300mg weekly treatment for patients aged 12 years and older with EoE.

The Dupixent application was assessed by the FDA under Priority Review, which is granted to therapies that have the potential to provide significant improvements in the treatment, diagnosis or prevention of serious conditions.